Toxoplasmosis Treatment | Market Size, Share & Growth Report 2025-2029
The Toxoplasmosis Treatment Market Report is Segmented by Drug Type (Pyrimethamine, Sulfadiazine, Clindamycin, Atovaquone, and Spiramycin), Treatment Type (Acute Treatment, Maintenance Therapy, and Prophylactic Therapy), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, and Online Pharmacies), Route of Administration (Oral and Intravenous).
Toxoplasmosis Treatment Market
Market Analysis
How the market stands today, and what is shaping it
The global toxoplasmosis treatment market was estimated at approximately USD 3.49 billion in 2025 and is projected to reach around USD 4.36 billion by 2029, representing a CAGR of approximately 5.72% during 2025–2029, based on Core Market Research estimates. The treatment pathway has not changed in decades and rests on pyrimethamine combined with sulfadiazine, with leucovorin given concomitantly to limit bone marrow suppression, while spiramycin is the drug of choice in maternal infection but holds no United States marketing authorisation. Market growth is supported by a large infected population, by restored generic supply of pyrimethamine following first generic approval in February 2020, and by established national screening programmes in France, Austria and Slovenia. Expansion is constrained by the roughly 90% of infections in immunocompetent people that are never diagnosed, by the absence of a national maternal screening programme in the United States, and by long-term declining seroprevalence. The market is supplied by generic manufacturers of long-established molecules rather than by companies developing toxoplasmosis-specific therapies, so competition turns on supply continuity, price and access. The December 2021 Federal Trade Commission settlement capping Daraprim at USD 1 per tablet for certain buyers, followed by Vyera Pharmaceuticals' Chapter 11 filing in May 2023, reset the economics of the pyrimethamine supply base.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Toxoplasma gondii infects more than 800,000 people annually in the United States, and an estimated 3,600 develop symptomatic eye disease with vision loss. Adult ocular disease is treated with pyrimethamine at 200 mg on day one then 50 mg daily for four weeks, so each diagnosis becomes a multi-week course.
- The December 2021 Federal Trade Commission settlement with Vyera Pharmaceuticals requires Daraprim to be supplied at no more than USD 1 per tablet to certain buyers and payment of up to USD 40 million over ten years. Capping the price of the reference product removes the cost barrier that had suppressed prescribing.
- Spiramycin is the drug of choice for maternal toxoplasmosis but is not approved in the United States, and clinicians obtain it on a compassionate basis directly from the FDA. That standing access route converts confirmed maternal infections into treated courses despite the absence of a domestic marketing authorisation.
- FDA approval of the first generic pyrimethamine on 28 February 2020 to Cerovene ended single-source supply. Dr. Reddy's brought a first-wave 25 mg tablet to market, with Teva and Oakrum Pharma also supplying the molecule, and that competition restored affordable access to a drug whose list price had risen roughly 5,000% in 2015.
- France has screened all susceptible pregnant women since 1985 and retested them monthly since 1992, and Austria and Slovenia operate comparable universal programmes. Systematic screening converts asymptomatic maternal infection into identified, treated cases, which is why European treated volume does not track incidence alone.
Market Challenges
- Roughly 90% of infections in immunocompetent people are asymptomatic, non-specific or self-limiting, so most infections are never diagnosed. The treated population is therefore a small fraction of the more than 800,000 people infected each year in the United States.
- The United States runs no national maternal screening programme, and Denmark and Switzerland have both stopped their nationwide screening. Where screening is absent, congenital infection is identified only after symptoms appear, which removes the prophylactic and maintenance courses that screening would have generated.
- Spiramycin has no United States marketing authorisation and must be requested from the FDA on a compassionate basis for each patient. That per-patient administrative step limits uptake of the drug that guidelines designate for maternal infection.
- Age-standardised seroprevalence among people aged 12 to 49 fell from 14.1% in 1988 to 1994, to 9% in 1999 to 2004, and to 6.7% in 2009 to 2010. A shrinking infected pool reduces the number of future reactivation and congenital cases that generate treatment demand.
- Pyrimethamine requires concomitant leucovorin to limit bone marrow suppression, which adds monitoring to every course. The regimen has not been displaced by a newer agent, so the market cannot rely on improved tolerability to widen the treated population.
Opportunities
- Toxoplasmosis is being reported in patients receiving biologics and small-molecule agents in autoimmune disease, oncology and transplantation. If iatrogenic immunosuppression continues to widen, prophylactic and maintenance courses could grow from a source independent of background infection rates.
- Vaccine work has moved to multi-epitope and nanoparticle designs, including a PLGA-carried Toxoplasma GAP45 candidate reported in 2025 and a GRA14, SAG1 and GRA1 multi-epitope design in 2026. A human vaccine could shift spending from treatment toward prevention, though all candidates remain preclinical.
- Prenatal screening in France is cost saving at EUR 212 per birth, and universal screening in 2020 would have saved an estimated EUR 148 million. Published economics of that quality may support adoption of screening in countries that currently have none, which would enlarge the treated population.
- Toxoplasmic retinochoroiditis is more severe in Brazil than in Europe, where it is a leading cause of blindness, and more virulent genotypes predominate in South America. That burden could support treatment demand in Latin America that is not reflected in current commercial supply.
- Formulation work such as a spiramycin nanoemulsion has been evaluated against Toxoplasma gondii tachyzoites. Improved delivery may in time address the difficulty of reaching therapeutic concentrations in the brain and eye, which is one of the stated obstacles to better treatment.
Trends and Insights
Key market trends shaping the industry landscape
Antitrust Remedy Reset the Pricing Floor
High impactShort-termPricing in this market is now shaped by competition enforcement as much as by supply, following the FTC action over Daraprim and the subsequent entry of generic pyrimethamine.
Insight: A settlement that caps the reference product at USD 1 per tablet for certain buyers sets a ceiling that generic entrants must price beneath, so revenue growth depends on treated volume rather than on price.
Reactivation Risk Shifting Toward Iatrogenic Causes
Medium impactMid-termCases are increasingly reported in patients immunosuppressed by biologics, targeted small molecules and transplantation rather than solely by untreated HIV infection.
Insight: If the at-risk population is defined by prescribed immunosuppression, demand becomes linked to the growth of those therapy classes, which is a different and more predictable driver than background infection rates.
National Screening Policy Is Diverging
Medium impactMid-termFrance, Austria and Slovenia maintain universal screening in pregnancy while Denmark and Switzerland have stopped their nationwide programmes, and the United States has never had one.
Insight: Screening policy, not infection rate, determines how many maternal infections become treated courses, so national treated volume can move in the opposite direction to national incidence.
Vaccine Work Consolidating on Multi-Epitope Designs
Low impactLong-termResearch has converged on multi-epitope and nanoparticle-delivered constructs using defined antigens such as GAP45, GRA14, SAG1 and GRA1, rather than on attenuated whole-organism approaches.
Insight: Toxovax is licensed only for sheep and cannot be given to people on safety grounds, so a human vaccine requires the subunit route. All candidates remain preclinical, so any commercial effect sits beyond the forecast period.
Segment Analysis
Market segmentation by drug type, treatment type, distribution channel, route of administration
The supplied categories are Pyrimethamine, Sulfadiazine, Clindamycin, Atovaquone and Spiramycin. No split of revenue by drug type is published for this market, so the categories are assessed by their role in guideline therapy. Pyrimethamine and sulfadiazine are used together as the standard combination, with leucovorin added to limit bone marrow suppression, so these two move together rather than competing. Clindamycin is the substitute where a sulfonamide cannot be used, which makes its volume dependent on sulfadiazine intolerance rather than on independent demand. Atovaquone is an FDA-approved alternative used in second-line and intolerant cases. Spiramycin sits apart from the others: it is the drug of choice for maternal infection and is used to reduce mother-to-child transmission, but it has no United States marketing authorisation and is obtained from the FDA on a compassionate basis. Its volume is therefore governed by screening policy and by that access route rather than by ordinary prescribing.
Geography Analysis
Regional market analysis
North America
North America carries the best-quantified disease burden and the most documented commercial activity. Annual infections in the United States exceed 800,000. Symptomatic eye disease leading to vision loss develops in an estimated 3,600 people a year, and congenital cases number between 300 and 4,000. Age-standardised seroprevalence in people aged 12 to 49 fell from 14.1% in 1988 to 1994, to 9% in 1999 to 2004, and to 6.7% in 2009 to 2010, with about 11% among women of childbearing age. There is no national maternal screening programme. The supply base was reset here: the FDA approved the first generic pyrimethamine on 28 February 2020, the FTC settled with Vyera Pharmaceuticals in December 2021, and Vyera filed for Chapter 11 in May 2023. Spiramycin remains unapproved in the United States and is obtained from the FDA on a compassionate basis. No regional market size, revenue or growth figure for North America was identified in the sources reviewed for this report. The regional ranking therefore rests on documented disease concentration and on the supply events recorded above rather than on a measured market figure.
Europe
Europe's position rests on screening policy rather than on a larger infected population. France has required that all susceptible pregnant women be identified at the first prenatal visit since 1985, and retested monthly since 1992. Austria and Slovenia have the longest comparable experience with universal programmes. The economics are documented: screening is cost saving at EUR 212 per birth, and universal screening in 2020 would have saved France an estimated EUR 148 million. Policy is not uniform, and Denmark and Switzerland have stopped their nationwide programmes. France also reports declining seroprevalence among pregnant women between 1995 and 2016, which has itself prompted debate over whether the programme should continue. Europe is also the home of spiramycin as Rovamycine, marketed by Sanofi, which is the agent United States clinicians must import through the FDA.
Asia Pacific
Asia Pacific has no identified national screening programme for toxoplasmosis in pregnancy comparable to those in France, Austria or Slovenia, and no regional incidence series of the quality available for the United States has been identified. The drugs used are not region-specific: pyrimethamine, sulfadiazine, clindamycin and atovaquone are established molecules supplied by generic manufacturers, and Teva and Dr. Reddy's both operate at global scale. Regional demand therefore depends on diagnostic capability and on whether maternal infection is identified before delivery, rather than on the availability of any proprietary product. Without published screening policy or incidence data for the region, any claim about its size or growth would not be supported by evidence.
Latin America
Latin America carries a distinct and better-documented clinical burden than its commercial activity suggests. Toxoplasmic retinochoroiditis is more severe in Brazil than in Europe, where it is a leading cause of blindness, and evidence indicates that more virulent genotypes of Toxoplasma gondii predominate in South America. That combination means the same infection produces more sight-threatening disease, and therefore more demand for the pyrimethamine and sulfonamide courses used in ocular disease. No regional screening programme of the French type has been identified, and no per-country treatment market data has been identified. The gap between a documented severe burden and undocumented commercial supply is the defining feature of the region.
Middle East & Africa
Middle East and Africa is the least documented region for this market. No national screening programme and no regional incidence series comparable to the United States or French data has been identified. The practical constraint is diagnosis rather than drug supply, because the molecules involved are long off patent and are produced by global generic manufacturers. Identifying maternal infection requires serological screening and confirmatory testing during pregnancy, and identifying reactivation requires access to imaging and specialist assessment. Where those services are limited, infection is treated only after severe disease appears, which removes the prophylactic and maintenance courses that account for a substantial part of treated volume elsewhere.
Competitive Landscape
Key players and market positioning analysis
Competition in the toxoplasmosis treatment market is organised around off-patent molecules rather than around proprietary products, which makes supply reliability and price the operative competitive factors. The guideline combination of pyrimethamine with sulfadiazine, given alongside leucovorin, has not been displaced by a newer agent, so no participant competes on clinical differentiation in first-line therapy. Participants fall into three cohorts. The first is the originator cohort holding branded products with defined roles. Sanofi supplies spiramycin as Rovamycine, the agent designated for maternal infection, and its position is unusual because the product has no United States marketing authorisation and reaches American patients through an FDA compassionate-use route rather than through commercial distribution. GSK holds atovaquone, an FDA-approved alternative used where the standard combination is not tolerated. The second cohort is the generic supply base for pyrimethamine, which was rebuilt after February 2020. The cohort comprises Dr. Reddy's, Teva and Oakrum Pharma, none of which holds a clinical advantage over the others. Competition in this cohort runs on price and continuity of supply, with no clinical differentiation available. The third position is occupied by a company that has left the market: Vyera Pharmaceuticals, formerly Turing, held the reference product Daraprim and filed for Chapter 11 in May 2023 under generic pressure and FTC litigation. Its exit is central to the current structure, because the December 2021 settlement capped Daraprim at no more than USD 1 per tablet for certain buyers and required payment of up to USD 40 million over ten years. That remedy set a price ceiling the generic cohort must work beneath. The decisive competitive factors are therefore regulatory access and supply continuity rather than efficacy. Future competitive differentiation may depend on whether any participant can bring forward a drug that clears tissue cysts or reaches therapeutic concentrations in the brain and eye, since those are the stated obstacles to improving on the existing regimen.
Major Players
Leading companies in the market
Industry Developments
9 recorded developments
A multi-epitope vaccine design using the GRA14, SAG1 and GRA1 antigens of Toxoplasma gondii was published, and a systematic review documented emerging toxoplasmosis cases linked to biologics and small molecules in autoimmune disease, oncology and transplantation.
A PLGA nanoparticle formulation carrying the Toxoplasma GAP45 antigen was reported as a more effective vaccine against acute toxoplasmosis than earlier approaches, part of a shift toward subunit designs after the failure of whole-organism routes in humans.
Vyera Pharmaceuticals filed for Chapter 11 bankruptcy in May, driven by generic pressure, declining profits and the FTC litigation over Daraprim, ending the commercial life of the branded reference product.
The FTC and state attorneys general settled with Vyera Pharmaceuticals in December, requiring Daraprim to be supplied at no more than USD 1 per tablet to certain buyers and payment of up to USD 40 million over ten years.
The Federal Trade Commission filed a complaint against Vyera Pharmaceuticals in January, alleging a scheme to block generic competition through closed distribution, exclusive supply agreements for the active ingredient and restrictions on sales data.
The FDA approved the first generic of Daraprim on 28 February to Cerovene, ending the single-source period, and Dr. Reddy's subsequently launched a first-wave generic pyrimethamine 25 mg tablet in the United States.
Turing Pharmaceuticals raised the list price of Daraprim by about 5,000% after acquiring it, making the reference pyrimethamine product a widely cited example of single-source pricing in an off-patent molecule.
France extended its programme to require monthly retesting of susceptible pregnant women until delivery, increasing the proportion of maternal infections detected early enough for spiramycin to reduce transmission.
France established mandatory systematic screening for toxoplasmosis in pregnancy, requiring that all susceptible pregnant women be identified at their first prenatal visit, which created the first national programme converting maternal infection into treated cases.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Drug Type
5.3 By Treatment Type
5.4 By Distribution Channel
5.5 By Route of Administration
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Sanofi
9.2 GSK plc
9.3 Teva Pharmaceutical Industries Limited
9.4 Dr. Reddy's Laboratories Limited
9.5 Oakrum Pharma
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2029
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Sanofi, GSK plc, Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.